Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy: Results from a prospective cohort study (personal)

Sabine Visser, Mark De Mol, Kiki Cheung, Jermo J. Van Toor, Nico C. Van Walree, Bruno H. Stricker*, B.L.. den Oudsten, Joachim G.j.v. Aerts

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

2 Citations (Scopus)

Abstract

Introduction.
In patients with advanced non–small-cell lung cancer, the treatment benefits and risks need to be constantly weighed. We explored patient-reported satisfaction with therapy (SWT) and assessed its value in addition to quality of life (QoL) and adverse events (AEs).

Patients and methods.
In a prospective multicenter cohort study, patients with stage IIIB/IV non–small-cell lung cancer received platinum-pemetrexed chemotherapy. They completed the World Health Organization Quality of Life-BREF (WHOQoL-BREF) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) before and during chemotherapy. After the last cycle, patients reported on SWT, expectations of therapy, and feelings about side effects (FSE) using the Cancer Therapy Satisfaction Questionnaire. The explained variance (R2) of QoL after treatment by SWT was calculated. Using multivariable linear regression, we examined the association of SWT with patient- and treatment-related variables, FSE, and AEs.

Results.
Eighty-nine patients finished 4 cycles of chemotherapy, 65 of whom completed the Cancer Therapy Satisfaction Questionnaire. Fifty-six patients (86.2%) would probably or definitely decide to undergo the same treatment again, regardless of deterioration or improvement in QoL or a high or low frequency of AEs during chemotherapy. The explained variance of QoL by SWT was greatest for the EORTC QLQ C-30 global health status/QoL scale (R2 = 0.170). Patient age (β = 0.43; 95% confidence interval [CI], 0.05-0.82), FSE (β = 0.17; 95% CI, 0.06-0.29), and tumor response (β = 7.93; 95% CI (1.64 to 14.22)) were independently associated with SWT.

Conclusion.
SWT could provide important supplementary information in addition to QoL assessments and treatment toxicities. Tumor response, older age, and FSE score were associated with better SWT. These insights could affect decision-making during palliative chemotherapy

Original languageEnglish
Pages (from-to)e503-e516
JournalClinical Lung Cancer
Volume19
Issue number4
DOIs
Publication statusPublished - 2018

Keywords

  • BREAST-CANCER
  • CTSQ
  • MAINTENANCE THERAPY
  • NSCLC
  • PATIENTS ATTITUDES
  • PATIENTS PREFERENCES
  • PEMETREXED PLUS CISPLATIN
  • PHASE-III
  • PLACEBO PLUS
  • Palliative chemotherapy
  • QUALITY-OF-LIFE
  • Quality of life
  • SUPPORTIVE CARE
  • Satisfaction with therapy
  • TRIAL

Fingerprint Dive into the research topics of 'Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy: Results from a prospective cohort study (personal)'. Together they form a unique fingerprint.

Cite this